Skip to main content
Erschienen in:

24.03.2021 | Original Paper

Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia

verfasst von: Richard Huan Xu, Dong Dong, Nan Luo, Eliza Lai-Yi Wong, Yushan Wu, Siyue Yu, Renchi Yang, Junshuai Liu, Huiqin Yuan, Shuyang Zhang

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to evaluate the psychometric properties of the EQ-5D-5L and SF-6D, and to compare their performance among patients living with haemophilia in China.

Methods

A total of 875 Chinese patients completed the EQ-5D-5L, SF-6D, and Haem-A-QoL questionnaires. Construct validity of the EQ-5D-5L and SF-6D dimensions and indices was assessed by testing hypotheses relating these measures to Haem-A-QoL and clinical measures. The Spearman correlation coefficient was used to assess convergent validity, and one-way analysis of variance (F statistic) was used to assess the known-groups validity (discriminatory power). The agreement between EQ-5D-5L and SF-6D indices was assessed using the intraclass correlation coefficient (ICC) and the Bland–Altman plot.

Results

Both the EQ-5D-5L and SF-6D indices showed acceptable ceiling and floor effects. As hypothesised, both EQ-5D-5L and SF-6D were significantly correlated with Haem-A-QoL (both dimensions and overall score). EQ-5D-5L and SF-6D indices as well as EQ-VAS differentiated patients are known to differ in severity of haemophilia, bleeding status, disabling levels, and comorbidity. The F statistics in the known-groups comparisons suggested that the EQ-5D-5L was slightly more discriminative than the SF-6D. ICC (0.41) and Bland–Altman plot confirmed that the agreement between the EQ-5D-5L and SF-6D indices was poor.

Conclusion

Both EQ-5D-5L and SF-6D showed satisfactory construct validity in the measurement of the HRQoL among patients with haemophilia. However, the two instruments may not be used interchangeably in this patient population due to their poor agreement and differing discriminatory power.
Literatur
17.
Zurück zum Zitat Mackensen, S., Gringeri, A.: Development and pilot testing of a disease-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL). Blood 104, 608A-609A (2004)CrossRef Mackensen, S., Gringeri, A.: Development and pilot testing of a disease-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL). Blood 104, 608A-609A (2004)CrossRef
18.
Zurück zum Zitat Young, N.L., Wakefield, C., Burke, T.A., et al.: Updating the Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT Version 2.0). Value Health 16, 837–841 (2013)CrossRefPubMed Young, N.L., Wakefield, C., Burke, T.A., et al.: Updating the Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT Version 2.0). Value Health 16, 837–841 (2013)CrossRefPubMed
20.
Zurück zum Zitat Varaklioti, A., Kontodimopoulos, N., Katsarou, O., et al.: Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients. Biomed Res Int 2014, 1–12 (2014) CrossRef Varaklioti, A., Kontodimopoulos, N., Katsarou, O., et al.: Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients. Biomed Res Int 2014, 1–12 (2014) CrossRef
22.
Zurück zum Zitat Trindade, G.C., Viggiano, L.G.L., Brant, E.R., et al.: Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. Hematol Transfus Cell Ther 41, 335–341 (2019)CrossRefPubMedPubMedCentral Trindade, G.C., Viggiano, L.G.L., Brant, E.R., et al.: Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. Hematol Transfus Cell Ther 41, 335–341 (2019)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Finch, A.P., Brazier, J.E., Mukuria, C.: What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. Eur J Health Econ 19, 557–570 (2017)CrossRefPubMedPubMedCentral Finch, A.P., Brazier, J.E., Mukuria, C.: What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. Eur J Health Econ 19, 557–570 (2017)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Abdin, E., Subramaniam, M., Vaingankar, J.A., et al.: Measuring health-related quality of life among adults in Singapore: population norms for the EQ-5D. Qual Life Res 22, 2983–2991 (2013)CrossRefPubMed Abdin, E., Subramaniam, M., Vaingankar, J.A., et al.: Measuring health-related quality of life among adults in Singapore: population norms for the EQ-5D. Qual Life Res 22, 2983–2991 (2013)CrossRefPubMed
29.
Zurück zum Zitat Soucie, J.M., Grosse, S.D., Siddiqi, A.E.A., et al.: The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States. Haemophilia 23, e287–e293 (2017)CrossRefPubMedPubMedCentral Soucie, J.M., Grosse, S.D., Siddiqi, A.E.A., et al.: The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States. Haemophilia 23, e287–e293 (2017)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Carroll, L., Benson, G., Lambert, J., et al.: Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adher 13, 941–957 (2019)CrossRef Carroll, L., Benson, G., Lambert, J., et al.: Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adher 13, 941–957 (2019)CrossRef
38.
Zurück zum Zitat Spilker, B.: Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia (1996) Spilker, B.: Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia (1996)
47.
Zurück zum Zitat Shah, R.M., Banahan, B.F., 3rd., Holmes, E.R., et al.: An evaluation of the psychometric properties of the sf-12v2 health survey among adults with hemophilia. Health Qual Life Outcomes 16, 229 (2018)CrossRefPubMedPubMedCentral Shah, R.M., Banahan, B.F., 3rd., Holmes, E.R., et al.: An evaluation of the psychometric properties of the sf-12v2 health survey among adults with hemophilia. Health Qual Life Outcomes 16, 229 (2018)CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat St-Louis, J., Urajnik, D.J., Ménard, F., et al.: Generic and disease-specific quality of life among youth and young men with hemophilia in Canada. BMC Hematol 16, 13 (2016)CrossRefPubMedPubMedCentral St-Louis, J., Urajnik, D.J., Ménard, F., et al.: Generic and disease-specific quality of life among youth and young men with hemophilia in Canada. BMC Hematol 16, 13 (2016)CrossRefPubMedPubMedCentral
55.
56.
Zurück zum Zitat Grosse, S.D., Chaugule, S.S., Hay, J.W.: Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res 15, 267–283 (2014)CrossRef Grosse, S.D., Chaugule, S.S., Hay, J.W.: Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res 15, 267–283 (2014)CrossRef
Metadaten
Titel
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia
verfasst von
Richard Huan Xu
Dong Dong
Nan Luo
Eliza Lai-Yi Wong
Yushan Wu
Siyue Yu
Renchi Yang
Junshuai Liu
Huiqin Yuan
Shuyang Zhang
Publikationsdatum
24.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 4/2021
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-021-01273-5